Drugs / Dalcetrapib
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01476267 | Oct → Nov 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01363999 | Jun → Jul 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 29 trials · 1 met primary | ||||||
| Phase 2 | NCT00655473 | Mar 2008 → Nov 2010 | coronary artery disorder | Hoffmann-La Roche | Completed | Met primary |
| Phase 2 | NCT00655538 | Feb 2008 → May 2010 | coronary artery disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00400439 | Jan 2007 → Jan 2008 | coronary artery disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00353522 | Jul 2006 → Oct 2008 | coronary artery disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00697203 | Jul 2005 → May 2006 | hyperlipidemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00688558 | Feb → Dec 2004 | hyperlipidemia | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00689442 | Jan → Nov 2004 | hyperlipidemia | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00688896 | Jun 2002 → Apr 2003 | hyperlipidemia | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00686010 | May 2000 → Jan 2001 | hyperlipidemia | Japan Tobacco Inc. | Completed | No outcome recorded |
| Phase 35 trials · 1 missed | ||||||
| Phase 3 | NCT05918861 | Oct 2023 → Aug 2027 expected | acute coronary syndrome | DalCor Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT01516541 | Jan → Jul 2012 | cardiovascular disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01323153 | Mar 2011 → Mar 2012 | coronary artery disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01059682 | Jan 2010 → Sep 2011 | cardiovascular disorder | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT00658515 | Apr 2008 → Sep 2012 | coronary artery disorder | Hoffmann-La Roche | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04676867 Comparator | Jan → May 2021 | COVID-19 | DalCor Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02525939 Comparator | Apr 2016 → Oct 2021 | acute coronary syndrome | DalCor Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dalcetrapib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01363999 ↗ |
| Known as | JTT-705 | “Efficacy and safety data for dalcetrapib (RO4607381/JTT-705) are presented” PMID 19576325 ↗ Jul 2009 |
| Known as | RO4607381 | “Drug: Dalcetrapib (RO4607381)” NCT00655473 ↗ |
| Action | Inhibit | “the CETP inhibitor dalcetrapib” PMID 32144166 ↗ Mar 2020 |
| Modality | Small molecule | — CHEMBL313006 ↗ |
| Route | Oral | “Dalcetrapib 900mg po daily for 24 weeks” NCT00353522 ↗ |
| Target | CETP | “Dalcetrapib, which targets cholesteryl ester transfer protein” PMID 20738227 ↗ Oct 2010 |